Paper36710948
Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.
Salvaris R and 8 others. Blood Cell Ther, 2022. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients. Papers, record 36710948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36710948
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24218510 | Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24218510 | PubMed |
| 2 | 24810613 | Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing. | Eur J Clin Pharmacol | 2014 | https://conductscience.org/library/papers/24810613 | PubMed |
| 3 | 23394705 | Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. | J Hematol Oncol | 2013 | https://conductscience.org/library/papers/23394705 | PubMed |
| 4 | 12374452 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. | Biol Blood Marrow Transplant | 2002 | https://conductscience.org/library/papers/12374452 | PubMed |
| 5 | 30372796 | Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. | J Intern Med | 2019 | https://conductscience.org/library/papers/30372796 | PubMed |
| 6 | 22406655 | Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. | Ther Drug Monit | 2012 | https://conductscience.org/library/papers/22406655 | PubMed |
| 7 | 8599861 | Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. | Cancer Chemother Pharmacol | 1996 | https://conductscience.org/library/papers/8599861 | PubMed |
| 8 | 30511436 | Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis. | Basic Clin Pharmacol Toxicol | 2019 | https://conductscience.org/library/papers/30511436 | PubMed |
| 9 | 21105791 | Reduced mortality after allogeneic hematopoietic-cell transplantation. | N Engl J Med | 2010 | https://conductscience.org/library/papers/21105791 | PubMed |
| 10 | 18215782 | High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18215782 | PubMed |
| 11 | 9108427 | Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. | Blood | 1997 | https://conductscience.org/library/papers/9108427 | PubMed |
| 12 | 24744269 | Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. | Blood | 2014 | https://conductscience.org/library/papers/24744269 | PubMed |
| 13 | 20711242 | Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. | Bone Marrow Transplant | 2011 | https://conductscience.org/library/papers/20711242 | PubMed |
| 14 | 21918171 | Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21918171 | PubMed |
| 15 | 23129746 | Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23129746 | PubMed |
| 16 | 15255794 | What is the best size descriptor to use for pharmacokinetic studies in the obese? | Br J Clin Pharmacol | 2004 | https://conductscience.org/library/papers/15255794 | PubMed |
| 17 | 22615660 | Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. | Daru | 2011 | https://conductscience.org/library/papers/22615660 | PubMed |
| 18 | 12374454 | Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. | Biol Blood Marrow Transplant | 2002 | https://conductscience.org/library/papers/12374454 | PubMed |
| 19 | 16133536 | Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. | Cancer Chemother Pharmacol | 2006 | https://conductscience.org/library/papers/16133536 | PubMed |
| 20 | 16785066 | Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. | Biol Blood Marrow Transplant | 2006 | https://conductscience.org/library/papers/16785066 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GSTK1 | 373156 | PubTator's text mining | https://conductscience.org/library/genes/373156 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36710948
GET https://conductscience.org/api/papers/v1/36710948/references?page=2